Literature DB >> 22682962

Metabolic syndrome and localization of white matter hyperintensities in the elderly population.

Florence Portet1, Adam M Brickman, Yaakov Stern, Nikolaos Scarmeas, Jordan Muraskin, Frank A Provenzano, Claudine Berr, Alain Bonafé, Sylvaine Artero, Karen Ritchie, Tasnime N Akbaraly.   

Abstract

BACKGROUND: Metabolic syndrome (MetS) is defined as a clustering of metabolic disorders: abdominal obesity, dyslipidemia, hypertension, and hyperglycemia. Although specific components of MetS have been associated with white matter hyperintensities (WMH), less is known about the association between MetS as a whole and WMH, especially in normal aging. We aimed to: (1) investigate this association in a cohort of healthy elderly individuals, and (2) examine the relationship between MetS and the regional distribution of WMH, to further understanding of the relationship between MetS and structural brain changes.
METHODS: Analyses were carried out on 308 participants (48.1% men, age: 71.0 ± 3.9 years) from the French longitudinal ESPRIT (Enquête de Santé Psychologique--Risques, Incidence et Traitement) study, who were free of cerebrovascular disease cognitive and functional impairment. Logistic regression models were used to examine the cross-sectional association between MetS (defined using the National Cholesterol Education Program-Adult Treatment Panel III criteria) and (1) WMH volumes, and (2) WMH volumes according to their localization in insulofrontal and temporoparietal regions.
RESULTS: After adjusting for potential confounders, participants with MetS had a twofold increased chance of presenting with high levels of WMH volume compared with those without (odds ratio [OR] = 2.74, 95% confidence interval [CI]: 1.25-6.03). MetS was specifically associated with an increase of temporoparietal WMH volumes, but no association was found between MetS and WMH localized in the insulofrontal region.
CONCLUSION: Our findings suggest that effective management of MetS may reduce WMH accumulation in brain areas already vulnerable to the aging process.
Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22682962      PMCID: PMC4108160          DOI: 10.1016/j.jalz.2011.11.007

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  46 in total

1.  Association of the metabolic syndrome with intracranial atherosclerotic stroke.

Authors:  O Y Bang; J W Kim; J H Lee; M A Lee; P H Lee; I S Joo; K Huh
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

Review 2.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 3.  Advances in the early detection of Alzheimer's disease.

Authors:  Peter J Nestor; Philip Scheltens; John R Hodges
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

4.  The metabolic syndrome and development of cognitive impairment among older women.

Authors:  Kristine Yaffe; Andrea L Weston; Terri Blackwell; Kathryn A Krueger
Journal:  Arch Neurol       Date:  2009-03

5.  The metabolic syndrome is associated with decelerated cognitive decline in the oldest old.

Authors:  E van den Berg; G J Biessels; A J M de Craen; J Gussekloo; R G J Westendorp
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

6.  Prevalence of DSM-IV psychiatric disorder in the French elderly population.

Authors:  K Ritchie; S Artero; I Beluche; M-L Ancelin; A Mann; A-M Dupuy; A Malafosse; J-P Boulenger
Journal:  Br J Psychiatry       Date:  2004-02       Impact factor: 9.319

7.  Significant association between leukoaraiosis and metabolic syndrome in healthy subjects.

Authors:  K Park; N Yasuda; S Toyonaga; S M Yamada; H Nakabayashi; M Nakasato; T Nakagomi; E Tsubosaki; K Shimizu
Journal:  Neurology       Date:  2007-05-30       Impact factor: 9.910

8.  Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging.

Authors:  Vincenzo Solfrizzi; Emanuele Scafato; Cristiano Capurso; Alessia D'Introno; Anna Maria Colacicco; Vincenza Frisardi; Gianluigi Vendemiale; Marzia Baldereschi; Gaetano Crepaldi; Antonio Di Carlo; Lucia Galluzzo; Claudia Gandin; Domenico Inzitari; Stefania Maggi; Antonio Capurso; Francesco Panza
Journal:  Neurobiol Aging       Date:  2009-12-31       Impact factor: 4.673

9.  Association between metabolic syndrome and previous ischemic lesions in patients with intracranial atherosclerotic stroke.

Authors:  Jong-Ho Park; Hyung-Min Kwon
Journal:  Clin Neurol Neurosurg       Date:  2007-12-04       Impact factor: 1.876

10.  Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study.

Authors:  Christelle Raffaitin; Henri Gin; Jean-Philippe Empana; Catherine Helmer; Claudine Berr; Christophe Tzourio; Florence Portet; Jean-François Dartigues; Annick Alpérovitch; Pascale Barberger-Gateau
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 19.112

View more
  17 in total

Review 1.  Contemplating Alzheimer's disease and the contribution of white matter hyperintensities.

Authors:  Adam M Brickman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

Review 2.  Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons.

Authors:  Hazel Mae A Abraham; Leslie Wolfson; Nicola Moscufo; Charles R G Guttmann; Richard F Kaplan; William B White
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

3.  White matter fiber-specific degeneration in older adults with metabolic syndrome.

Authors:  Christina Andica; Koji Kamagata; Wataru Uchida; Kaito Takabayashi; Keigo Shimoji; Hideyoshi Kaga; Yuki Someya; Yoshifumi Tamura; Ryuzo Kawamori; Hirotaka Watada; Masaaki Hori; Shigeki Aoki
Journal:  Mol Metab       Date:  2022-06-09       Impact factor: 8.568

Review 4.  Pathways to Brain Aging and Their Modifiers: Free-Radical-Induced Energetic and Neural Decline in Senescence (FRIENDS) Model - A Mini-Review.

Authors:  Naftali Raz; Ana M Daugherty
Journal:  Gerontology       Date:  2017-09-01       Impact factor: 5.140

5.  Competing physiological pathways link individual differences in weight and abdominal adiposity to white matter microstructure.

Authors:  Timothy D Verstynen; Andrea Weinstein; Kirk I Erickson; Lei K Sheu; Anna L Marsland; Peter J Gianaros
Journal:  Neuroimage       Date:  2013-04-29       Impact factor: 6.556

6.  Metabolic Syndrome and Physical Performance: The Moderating Role of Cognition among Middle-to-Older-Aged Adults.

Authors:  Elisa F Ogawa; Elizabeth Leritz; Regina McGlinchey; William Milberg; Jonathan F Bean
Journal:  J Int Neuropsychol Soc       Date:  2020-08-10       Impact factor: 2.892

7.  Metabolic Syndrome and Amyloid Accumulation in the Aging Brain.

Authors:  Gabriela Gomez; Lori L Beason-Held; Murat Bilgel; Yang An; Dean F Wong; Stephanie Studenski; Luigi Ferrucci; Susan M Resnick
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

8.  Longitudinal effects of metabolic syndrome on Alzheimer and vascular related brain pathology.

Authors:  Feng Lin; Raymond Y Lo; Daniel Cole; Simon Ducharme; Ding-Geng Chen; Mark Mapstone; Anton Porsteinsson
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-06-28

Review 9.  Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors.

Authors:  Mekala R Raman; Kejal Kantarci; Melissa E Murray; Clifford R Jack; Prashanthi Vemuri
Journal:  Alzheimers Dement (Amst)       Date:  2016-12-18

10.  APOE ε4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?

Authors:  Adam M Brickman; Nicole Schupf; Jennifer J Manly; Yaakov Stern; José A Luchsinger; Frank A Provenzano; Atul Narkhede; Qolamreza Razlighi; Lyndsey Collins-Praino; Sylvaine Artero; Tasnime N Akbaraly; Karen Ritchie; Richard Mayeux; Florence Portet
Journal:  Alzheimers Dement       Date:  2014-10-07       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.